Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down - Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s share price gapped down before the market opened on Tuesday . The stock had previously closed at $2.18, but opened at $2.12. Autolus Therapeutics shares last traded at $2.14, with a volume of 615,672 shares trading hands.

Analyst Ratings Changes

Several research firms have recently commented on AUTL. Needham & Company LLC reiterated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, December 5th. Redburn Atlantic upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target on the stock in a research note on Friday, November 15th. Finally, The Goldman Sachs Group raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics currently has a consensus rating of "Buy" and an average price target of $10.40.

Autolus Therapeutics Price Performance

The stock has a fifty day simple moving average of $3.33 and a 200-day simple moving average of $3.75. The company has a market capitalization of $598.71 million, a price-to-earnings ratio of -1.86 and a beta of 1.99.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same quarter in the previous year, the business posted ($0.26) earnings per share. As a group, equities analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AUTL. ProShare Advisors LLC purchased a new position in Autolus Therapeutics in the 2nd quarter valued at $43,000. Capstone Investment Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the third quarter valued at about $51,000. Daiwa Securities Group Inc. boosted its holdings in Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after purchasing an additional 15,293 shares during the last quarter. Herbst Group LLC acquired a new position in Autolus Therapeutics in the 3rd quarter valued at about $91,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company's stock valued at $139,000 after buying an additional 14,959 shares during the period. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.